US20040122000A1
(en)
*
|
1981-01-07 |
2004-06-24 |
Vertex Pharmaceuticals Incorporated. |
Inhibitors of aspartyl protease
|
US6878728B1
(en)
|
1999-06-11 |
2005-04-12 |
Vertex Pharmaceutical Incorporated |
Inhibitors of aspartyl protease
|
US5614533A
(en)
*
|
1987-03-13 |
1997-03-25 |
Bio-Mega/Boehringer Ingelheim Research, Inc. |
Substituted pipecolinic acid derivatives as HIV protease inhibitors
|
USH1649H
(en)
|
1987-07-31 |
1997-05-06 |
Barrish; Joel C. |
HIV protease inhibitor combinations
|
CA1340588C
(fr)
*
|
1988-06-13 |
1999-06-08 |
Balraj Krishan Handa |
Derive d'aminoacides
|
GB8927915D0
(en)
*
|
1989-12-11 |
1990-02-14 |
Hoffmann La Roche |
Novel alcohols
|
US5430041A
(en)
*
|
1991-05-10 |
1995-07-04 |
Hoffmann-La Roche Inc. |
Amino acid derivatives having antiviral activity
|
CN1071930A
(zh)
*
|
1991-07-10 |
1993-05-12 |
伊莱利利公司 |
用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
|
US5508407A
(en)
*
|
1991-07-10 |
1996-04-16 |
Eli Lilly And Company |
Retroviral protease inhibitors
|
WO1993008184A1
(fr)
*
|
1991-10-23 |
1993-04-29 |
Merck & Co., Inc. |
Inhibiteurs de la protease du vih______________________
|
DK0541168T3
(da)
*
|
1991-11-08 |
1998-05-11 |
Merck & Co Inc |
HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
|
US5413999A
(en)
*
|
1991-11-08 |
1995-05-09 |
Merck & Co., Inc. |
HIV protease inhibitors useful for the treatment of AIDS
|
US5888992A
(en)
|
1992-03-11 |
1999-03-30 |
Narhex Limited |
Polar substituted hydrocarbons
|
US5679688A
(en)
|
1992-03-11 |
1997-10-21 |
Narhex Limited |
Quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons
|
US6071895A
(en)
|
1992-03-11 |
2000-06-06 |
Narhex Limited |
Polar-substituted hydrocarbons
|
EP0560268B1
(fr)
*
|
1992-03-13 |
1995-01-04 |
Bio-Mega/Boehringer Ingelheim Research Inc. |
Dérivés de l'acide pipécolinic comme inhibiteurs de HIV-protéase
|
ATE199545T1
(de)
*
|
1992-05-21 |
2001-03-15 |
Monsanto Co |
Inhibitoren retroviraler proteasen
|
US5559256A
(en)
*
|
1992-07-20 |
1996-09-24 |
E. R. Squibb & Sons, Inc. |
Aminediol protease inhibitors
|
ES2123065T3
(es)
|
1992-08-25 |
1999-01-01 |
Searle & Co |
Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
|
US5723490A
(en)
*
|
1992-09-08 |
1998-03-03 |
Vertex Pharmaceuticals Incorporated |
THF-containing sulfonamide inhibitors of aspartyl protease
|
IS2334B
(is)
*
|
1992-09-08 |
2008-02-15 |
Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) |
Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
|
US5783701A
(en)
*
|
1992-09-08 |
1998-07-21 |
Vertex Pharmaceuticals, Incorporated |
Sulfonamide inhibitors of aspartyl protease
|
TW372972B
(en)
*
|
1992-10-23 |
1999-11-01 |
Novartis Ag |
Antiretroviral acyl compounds
|
US5380849A
(en)
*
|
1992-11-09 |
1995-01-10 |
Merck & Co., Inc. |
Process for optically pure decahydroisoqiunolines
|
US5430150A
(en)
*
|
1992-12-16 |
1995-07-04 |
American Cyanamid Company |
Retroviral protease inhibitors
|
US5491166A
(en)
*
|
1992-12-22 |
1996-02-13 |
Eli Lilly And Company |
Inhibitors of HIV protease useful for the treatment of AIDS
|
US5484926A
(en)
*
|
1993-10-07 |
1996-01-16 |
Agouron Pharmaceuticals, Inc. |
HIV protease inhibitors
|
US5434265A
(en)
*
|
1992-12-22 |
1995-07-18 |
Eli Lilly And Company |
Inhibitors of HIV protease
|
US5733906A
(en)
*
|
1993-10-12 |
1998-03-31 |
Eli Lilly And Company |
Inhibitors of HIV Protease useful for the treatment of Aids
|
US5846993A
(en)
*
|
1992-12-22 |
1998-12-08 |
Agouron Pharmaceuticals, Inc. |
HIV protease inhibitors
|
MX9308025A
(es)
*
|
1992-12-22 |
1994-08-31 |
Lilly Co Eli |
Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
|
MX9308016A
(es)
*
|
1992-12-22 |
1994-08-31 |
Lilly Co Eli |
Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
|
AU6161794A
(en)
*
|
1993-01-17 |
1994-08-15 |
Schering Corporation |
Peptides having anti-hiv activity
|
US5939430A
(en)
*
|
1993-02-22 |
1999-08-17 |
Merrell Pharmaceuticals Inc. |
Combinations of retroviral inhibitors
|
US5455353A
(en)
*
|
1993-03-24 |
1995-10-03 |
Hoffmann-La Roche Inc. |
4-(benzyl-2-oxo-oxazolidin-5 ylmethyl)N tertbutyl-decahydroisoquinoline-3-carboxamides
|
ATE149162T1
(de)
*
|
1993-07-15 |
1997-03-15 |
Hoffmann La Roche |
Verfahren zur herstellung eines n- tert.butylisochinolin-3-carboxamid derivates und zwischenprodukte in diesem verfahren
|
BR9408531A
(pt)
*
|
1994-02-02 |
1997-08-05 |
Lilly Co Eli |
Inibidores da protease hiv e intermediários
|
DE69512220T2
(de)
*
|
1994-03-07 |
2000-03-16 |
Vertex Pharmaceuticals Inc. |
Sulfonamidderivate als aspartylprotease-inhibitoren
|
US5527829A
(en)
*
|
1994-05-23 |
1996-06-18 |
Agouron Pharmaceuticals, Inc. |
HIV protease inhibitors
|
US5470979A
(en)
*
|
1994-07-01 |
1995-11-28 |
American Cyanamid Company |
Asymmetric synthesis of bicyclic amino acid esters
|
US5523463A
(en)
*
|
1994-09-23 |
1996-06-04 |
Hoffmann-La Roche Inc. |
Method of producing halogenated and alpha-aminoalchohols
|
US5591885A
(en)
*
|
1994-09-23 |
1997-01-07 |
Hoffman-La Roche Inc. |
Process for the preparation of halogenated α-aminoketone compounds
|
US5691372A
(en)
*
|
1995-04-19 |
1997-11-25 |
Vertex Pharmaceuticals Incorporated |
Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
|
US6008228A
(en)
*
|
1995-06-06 |
1999-12-28 |
Hoffman-La Roche Inc. |
Pharmaceutical compositions containing proteinase inhibitors
|
PT831826E
(pt)
*
|
1995-06-06 |
2003-02-28 |
Hoffmann La Roche |
Composicao farmaceutica que inclui um inibidor de proteinase e um monoglicerideo
|
US6004957A
(en)
*
|
1995-06-07 |
1999-12-21 |
Vertex Pharmaceuticals, Incorporated |
Sulfonamide inhibitors of aspartyl protease
|
AU759386B2
(en)
*
|
1995-06-29 |
2003-04-10 |
Abbvie Inc. |
Use of Ritonavir (ABT-538) for improving the pharmacokinetics of drugs metabolized by cytochrome P450 in a method of treating AIDS
|
US6037157A
(en)
|
1995-06-29 |
2000-03-14 |
Abbott Laboratories |
Method for improving pharmacokinetics
|
CA2235394A1
(fr)
|
1995-11-13 |
1997-05-22 |
Gerard Voerman |
Isolats antiviraux pouvant etre obtenus a partir de sangsues
|
US5914332A
(en)
*
|
1995-12-13 |
1999-06-22 |
Abbott Laboratories |
Retroviral protease inhibiting compounds
|
US5883252A
(en)
*
|
1996-01-26 |
1999-03-16 |
Vertex Pharmaceuticals Incorporated |
Aspartyl protease inhibitors
|
US5587481A
(en)
*
|
1996-02-20 |
1996-12-24 |
The Monsanto Company |
Preparation of (S)-decahydroisoquinoline-3-carboxylic acid t-butylamide
|
EP0823424A1
(fr)
*
|
1996-08-09 |
1998-02-11 |
F. Hoffmann-La Roche Ag |
Procédé pour la préparation de quinargine
|
US5914404A
(en)
*
|
1996-08-09 |
1999-06-22 |
Hoffmann-La Roche Inc. |
Process for the preparation of quinargine
|
US5925759A
(en)
|
1996-09-05 |
1999-07-20 |
Agouron Pharmaceuticals, Inc. |
Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
|
US5705647A
(en)
*
|
1996-09-05 |
1998-01-06 |
Agouron Pharmaceuticals, Inc. |
Intermediates for making HIV-protease inhibitors
|
US5962725A
(en)
|
1996-09-05 |
1999-10-05 |
Agouron Pharmaceuticals, Inc. |
Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
|
US6232333B1
(en)
|
1996-11-21 |
2001-05-15 |
Abbott Laboratories |
Pharmaceutical composition
|
DE59709770D1
(de)
|
1996-12-11 |
2003-05-15 |
Hoffmann La Roche |
Verfahren zur Herstellung gemischter Anhydride
|
US6001851A
(en)
*
|
1997-03-13 |
1999-12-14 |
Agouron Pharmaceuticals, Inc. |
HIV protease inhibitors
|
US6084107A
(en)
*
|
1997-09-05 |
2000-07-04 |
Agouron Pharmaceuticals, Inc. |
Intermediates for making HIV-protease inhibitors
|
US6143742A
(en)
*
|
1997-12-11 |
2000-11-07 |
Fuisz Technologies Ltd |
Treatment for necrotizing infections
|
US6436989B1
(en)
*
|
1997-12-24 |
2002-08-20 |
Vertex Pharmaceuticals, Incorporated |
Prodrugs of aspartyl protease inhibitors
|
FR2779653B1
(fr)
*
|
1998-06-11 |
2002-12-20 |
Inst Nat Sante Rech Med |
Utilisation de composes modulateurs du proteasome en therapie
|
DK1086076T3
(da)
*
|
1998-06-19 |
2005-03-29 |
Vertex Pharma |
Sulfonamidinhibitorer af aspartylprotease
|
KR100277723B1
(ko)
|
1998-12-14 |
2001-01-15 |
남창우 |
광학적으로 순수한 데카하이드로이소퀴놀린카르복사미드의 연속제조공정
|
US7635690B2
(en)
*
|
1999-01-22 |
2009-12-22 |
Emory University |
HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
|
US7115584B2
(en)
*
|
1999-01-22 |
2006-10-03 |
Emory University |
HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
|
US6765019B1
(en)
*
|
1999-05-06 |
2004-07-20 |
University Of Kentucky Research Foundation |
Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
|
TR200103488T2
(tr)
*
|
1999-06-04 |
2002-04-22 |
Abbott Laboratories |
Geliştirilmiş farmasötik formülasyonlar.
|
EP1202626A4
(fr)
*
|
1999-07-20 |
2002-10-30 |
Merck & Co Inc |
Derives alpha-hydroxy-gamma-[[(carbocycliques-ou heterocycliques-substitues)amino]carbonyle]alcanamide et utilisations de ceux-ci
|
US6589962B1
(en)
|
1999-07-20 |
2003-07-08 |
Merck & Co., Inc. |
Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
|
ES2295068T3
(es)
|
1999-11-24 |
2008-04-16 |
MERCK & CO., INC. |
Gamma-hidroxi-2-(fluoroalquilaminocarbonil)-1-piperazinpentanamidas como inhibidores de la proteasa del vih.
|
IT1313682B1
(it)
*
|
1999-11-25 |
2002-09-09 |
Archimica Spa |
Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
|
CA2395987C
(fr)
|
2000-01-19 |
2009-12-22 |
Abbott Laboratories |
Formulations pharmaceutiques ameliorees
|
AU2001259817A1
(en)
*
|
2000-05-04 |
2001-11-12 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health |
Methods of and compounds for inhibiting calpains
|
IT1318986B1
(it)
*
|
2000-10-09 |
2003-09-19 |
Archimica S P A Ora Clariant L |
Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
|
GB0028483D0
(en)
|
2000-11-22 |
2001-01-10 |
Hoffmann La Roche |
Hydroxyethylamine HIV protease inhibitors
|
US20030191121A1
(en)
*
|
2001-08-09 |
2003-10-09 |
Miller Ross A. |
Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
|
US7087418B2
(en)
|
2001-12-19 |
2006-08-08 |
Bristol-Myers Squibb Company |
Pichia pastoris formate dehydrogenase and uses therefor
|
US20040067216A1
(en)
*
|
2002-02-22 |
2004-04-08 |
Karki Shyam B. |
Hiv protease inhibitors supported on cation exchange resins for oral administration
|
IL163666A0
(en)
|
2002-02-22 |
2005-12-18 |
New River Pharmaceuticals Inc |
Active agent delivery systems and methods for protecting and administering active agents
|
US7157489B2
(en)
*
|
2002-03-12 |
2007-01-02 |
The Board Of Trustees Of The University Of Illinois |
HIV protease inhibitors
|
WO2003106405A1
(fr)
*
|
2002-06-01 |
2003-12-24 |
Sunesis Pharmaceuticals, Inc. |
Inhibiteurs de l'aspartyl-protease
|
US7115652B2
(en)
*
|
2002-06-17 |
2006-10-03 |
Sunesis Pharmaceuticals, Inc. |
Aspartyl protease inhibitors
|
BRPI0412523A
(pt)
*
|
2003-07-11 |
2006-09-19 |
Hoffmann La Roche |
forma de dosagem oral de mesilato de saquinavir
|
EP1604662A1
(fr)
*
|
2004-06-08 |
2005-12-14 |
Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft |
Derivés de la benzyl amine du acide carboxylique (2R) de la 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine et composés similaires pour l'utilisation comme inhibiteurs de la peptidase dipeptidyl IV (DPP-IV) pour le traitement de la diabetes mellitus de type 2
|
UA88313C2
(ru)
|
2004-07-27 |
2009-10-12 |
Гилиад Сайенсиз, Инк. |
Фосфонатные аналоги соединений ингибиторов вич
|
WO2006134612A1
(fr)
*
|
2005-06-16 |
2006-12-21 |
Hetero Drugs Limited |
Procédé de préparation du saquinavir à l’aide d’un nouvel intermédiaire
|
CN101631568B
(zh)
|
2007-03-12 |
2012-08-22 |
尼克塔治疗公司 |
低聚物-蛋白酶抑制剂偶联物
|
WO2009006203A1
(fr)
*
|
2007-06-29 |
2009-01-08 |
Gilead Sciences, Inc. |
Compositions thérapeutiques et leur utilisation
|
JP5547066B2
(ja)
*
|
2007-06-29 |
2014-07-09 |
ギリアード サイエンシーズ, インコーポレイテッド |
治療用組成物およびその使用
|
WO2009042093A1
(fr)
*
|
2007-09-25 |
2009-04-02 |
Merck & Co., Inc. |
Inhibiteurs de la protéase du vih
|
WO2009114151A1
(fr)
*
|
2008-03-12 |
2009-09-17 |
Nektar Therapeutics |
Conjugués oligomères-acides aminés et oligomères-atazanavir
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
EA021377B9
(ru)
|
2008-12-09 |
2015-09-30 |
Джилид Сайэнс, Инк. |
Модуляторы толл-подобных рецепторов
|
SG172363A1
(en)
|
2008-12-23 |
2011-07-28 |
Pharmasset Inc |
Synthesis of purine nucleosides
|
WO2010075517A2
(fr)
*
|
2008-12-23 |
2010-07-01 |
Pharmasset, Inc. |
Analogues de nucléoside
|
CL2009002207A1
(es)
|
2008-12-23 |
2011-02-18 |
Gilead Pharmasset Llc |
Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
|
JP2012528160A
(ja)
|
2009-05-27 |
2012-11-12 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Hivプロテアーゼ阻害薬
|
EP2440249A2
(fr)
|
2009-06-12 |
2012-04-18 |
Nektar Therapeutics |
Conjugués covalents comprenant un inhibiteurs de protéase, un oligomère non-peptidique soluble dans l'eau et une partie lipophilique
|
DE102010004957A1
(de)
|
2010-01-14 |
2011-07-21 |
Universitätsklinikum Jena, 07743 |
Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung
|
US20110223131A1
(en)
|
2010-02-24 |
2011-09-15 |
Gilead Sciences, Inc. |
Antiviral compounds
|
AP3515A
(en)
|
2010-03-31 |
2016-01-11 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
EP2632895B1
(fr)
|
2010-10-28 |
2018-10-03 |
Merck Canada Inc. |
Inhibiteurs de la protéase du vih
|
EP2392926A1
(fr)
|
2011-02-09 |
2011-12-07 |
Roche Diagnostics GmbH |
Biomarqueurs urinaires chez des sujets infectés par le VIH
|
EP2771332B1
(fr)
|
2011-10-26 |
2016-06-29 |
Merck Canada Inc. |
Dérivés sulfonamides de thiophen et thiazol en tant qu'inhibiteurs de la protease du HIV pour le traitement du SIDA
|
IN2012DE00082A
(fr)
|
2012-01-10 |
2015-05-01 |
Council Scient Ind Res |
|
US9315475B2
(en)
|
2012-09-11 |
2016-04-19 |
Merck Sharp & Dohme Corp. |
HIV protease inhibitors
|
US9227990B2
(en)
|
2012-10-29 |
2016-01-05 |
Cipla Limited |
Antiviral phosphonate analogues and process for preparation thereof
|
WO2015013835A1
(fr)
|
2013-07-31 |
2015-02-05 |
Merck Sharp & Dohme Corp. |
Dérivés de pipérazine utilisés en tant qu'inhibiteurs de la protéase du vih
|
EP3083609B1
(fr)
|
2013-12-19 |
2018-08-15 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de la protéase du vih
|
WO2015095276A1
(fr)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de la protéase du vih
|
EP3113780B1
(fr)
|
2014-03-06 |
2019-08-14 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de la protéase du vih
|
US10138255B2
(en)
|
2014-03-10 |
2018-11-27 |
Merck Sharp & Dohme Corp. |
Piperazine derivatives as HIV protease inhibitors
|
WO2016001907A1
(fr)
|
2014-07-02 |
2016-01-07 |
Prendergast Patrick T |
Mogroside iv et mogroside v utilisables en tant qu'agonistes/stimulateurs/agents de déblocage des récepteurs toll 4 et adjuvant destiné à être utilisé dans un vaccin humain/animal et pour stimuler l'immunité contre des agents pathologiques
|
TWI806081B
(zh)
|
2014-07-11 |
2023-06-21 |
美商基利科學股份有限公司 |
用於治療HIV之toll樣受體調節劑
|
EP3212196A4
(fr)
|
2014-10-29 |
2018-07-11 |
Wisconsin Alumni Research Foundation |
Inhibiteurs de protéase de vih à base d'acide borique
|
EP3349757A1
(fr)
|
2015-09-15 |
2018-07-25 |
Gilead Sciences, Inc. |
Modulateurs de récepteurs de type toll pour le traitement du vih
|
US20230218644A1
(en)
|
2020-04-16 |
2023-07-13 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|